Expanding the Paradigm of Structure-Based Drug Design: Molecular Dynamics Simulations Support the Development of New Pyridine-Based Protein Kinase C-Targeted Agonists

Protein kinase C (PKC) modulators hold therapeutic potential for various diseases, including cancer, heart failure, and Alzheimer's disease. Targeting the C1 domain of PKC represents a promising strategy; the available protein structures warrant the design of PKC-targeted ligands via a structure-based approach. However, the PKC C1 domain penetrates the lipid membrane during binding, complicating the design of drug candidates. The standard docking-scoring approach for PKC lacks information regarding the dynamics and the membrane environment. Molecular dynamics (MD) simulations with PKC, ligands, and membranes have been used to address these shortcomings. Previously, we observed that less computationally intensive simulations of just ligand-membrane interactions may help elucidate C1 domain-binding prospects. Here, we present the design, synthesis, and biological evaluation of new pyridine-based PKC agonists implementing an enhanced workflow with ligand-membrane MD simulations. This workflow holds promise to expand the approach in drug design for ligands targeted to weakly membrane-associated proteins.

Automated summary

Protein kinase C (PKC) modulators have therapeutic potential for various diseases. Targeting the C1 domain of PKC is a promising strategy, but the penetration of the lipid membrane complicates drug design. Molecular dynamics (MD) simulations with PKC, ligands, and membranes have been used to address these challenges. Here, we present the design, synthesis, and evaluation of new PKC agonists using an enhanced workflow with ligand-membrane MD simulations, which could be beneficial in designing ligands for weakly membrane-associated proteins.